The gross proceeds are subject to a 0.5 percent transfer tax, and net proceeds are subject to exchange rate fluctuations...If that works out, we'll start a clinical commercial development program next year," Ignon said...The money will fund ongoing product development, including the company's clinical trials and the expansion of manufacturing capabilities and general corporate purposes

Net proceeds are expected to go toward the development of Myogen's product candidates and research program, including the acceleration and expansion of its darusentan clinical program, as well as the preparation of the potential commercial launch of ambrisentan and darusentan

The company expects to use the proceeds for research and development, clinical trials, product manufacturing, intellectual property protection and working capital...Quintiles expects to use the net proceeds to repay in full all outstanding term loans under its existing senior secured credit facility, and for any other debt arrangements and general corporate purposes

brought in $20.4 million in a second-round Series C financing to advance its clinical programs in autoimmune and metabolic disorders...The company said net proceeds will be used to fund Phase II trials of its therapeutic vaccines to treat cancer and infectious diseases

Net proceeds from both offerings are expected to pay outstanding debt, as well as support ongoing clinical development of the company's cardiovascular products and other business activities...The remaining net proceeds will go toward business operations, which could include preclinical and clinical trials, research and development, regulatory filings and product commercialization costs

Net proceeds are expected to total about $29.3 million...Net proceeds of the offering will be used to repay the company's outstanding indebtedness to an affiliate of Dublin, Ireland-based Elan Corp

The company has two clinical-stage products: NGX424, a non-opioid, non-vascular compound licensed from Indianapolis-based Eli Lilly and Co., is in Phase I study for the treatment of acute migraine, and TorreyPines plans to file an investigational new drug application this spring for its NGX267 drug for Alzheimer's disease...Net proceeds are expected to total $32.8 million

If underwriters purchase an additional 600,000 shares to cover overallotments, Neurochem anticipates total net proceeds of $58.5 million...Neurologix Research develops treatments for disorders of the brain and central nervous system using gene therapies.

The Warrington, Pa.-based company estimates net proceeds to total about $25 million, which will help fund the anticipated market launch of Surfaxin, a prophylaxis therapy for respiratory distress syndrome, as well as ongoing clinical trials and general corporate purposes

Net proceeds "will primarily go toward our ongoing clinical development programs," said Jacques Lapointe, ConjuChem president and CEO

Net proceeds are expected to fund clinical trials of Telcyta, a cell-activated chemotherapeutic, and Telintra, a small molecule designed to treat myelodysplastic syndrome

Net proceeds were expected to reach about $72.8 million and be used to fund post-enrollment activities in Northfield's PolyHeme trial, including the submission of a biologics license application and construction of a manufacturing plant in Mt...announced net proceeds of $56.4 million after the closing of its common stock offering of 7.5 million shares at $8 apiece

In it, the agency had requested additional clinical data to identify a patient population and method of use for Symlin in which there is no increased risk of significant hypoglycemia or where there is an added benefit that clearly counterbalances any potential for increases in episodes of hypoglycemia...Public Stock Sale Nets $70.8M For Martek Martek Biosciences Corp., a maker of fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection, is expecting to

Though the offering grossed about $79.6 million, NitroMed expects to receive net proceeds of $74.2 million to cover general corporate purposes, in addition to a potential BiDil launch...The 73-person company has one marketed product, Inversine, and four candidates in clinical development, as well as several others at the preclinical stage

Four of those have advanced into clinical trials, including telavancin...They now have eight candidates, five of which are in clinical trials...The company has three products in clinical trials, and is conducting eight Phase II trials and one Phase III registration trial

Vasogen expects net proceeds from the offering to be around C$61.9 million, not including funds from the overallotment option...In addition to funding clinical trials of Celacade, the company plans to cover regulatory expenses for the drug

With an anticipated $54 million in net proceeds, the company plans to use the money for discovery and development, as well as for product manufacturing and other corporate purposes...The company expects net proceeds to be about $37.7 million, or $43.4 million if the underwriters exercise in full the overallotment option

The cancer therapeutics company said in its prospectus it plans to use net proceeds to fund clinical trials and other research and development expenses...are acting as co-managers.

raised net proceeds of about $49 million after pricing a public offering of 10 million common shares at $5.25 apiece...Though it has no clinical candidates, Lexicon has more than 20 targets in drug discovery programs